Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer
Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV−) OPC, before and after radiotherapy/chemo...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-06, Vol.13 (13), p.3256 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 13 |
| container_start_page | 3256 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Brewczyński, Adam Jabłońska, Beata Mazurek, Agnieszka Maria Mrochem-Kwarciak, Jolanta Mrowiec, Sławomir Śnietura, Mirosław Kentnowski, Marek Kołosza, Zofia Składowski, Krzysztof Rutkowski, Tomasz |
| description | Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV−) OPC, before and after radiotherapy/chemoradiotherapy (RT/CRT) and to assess the impact of these parameters on survival. One hundred twenty seven patients with HPV+ and HPV− OPC, treated with RT alone or concurrent chemoradiotherapy (CRT), were included. Patients were divided according to HPV status. Confirmation of HPV etiology was obtained from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue samples and/or extracellular circulating HPV DNA was determined. The pre-treatment and post-treatment laboratory blood parameters were compared in both groups. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and systemic immune inflammation (SII) index were calculated. The impact of these parameters on overall (OS) and disease-free (DFS) survival was analyzed. In HPV+ patients, a high pre-treatment white blood cells (WBC) count (>8.33 /mm3), NLR (>2.13), SII (>448.60) significantly correlated with reduced OS, whereas high NLR (>2.29), SII (>462.58) significantly correlated with reduced DFS. A higher pre-treatment NLR and SII were significant poor prognostic factors for both OS and DFS in the HPV+ group. These associations were not apparent in HPV− patients. There are different pre-treatment and post-treatment immune and hematological prognostic factors for OS and DFS in HPV+ and HPV− patients. The immune ratios could be considered valuable biomarkers for risk stratification and differentiation for HPV− and HPV+ OPC patients. |
| doi_str_mv | 10.3390/cancers13133256 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8268778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548400845</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-23da055ad9f0083819e80612d4651f7bc36e6ce516f10e3ff1b5973d90d456783</originalsourceid><addsrcrecordid>eNpdkUtr3DAUhUVpaUKadbaCbrpxo4clW5tCGdpMIJDQPLZCI1_PKNiSK8lT8lv6Z6OZDKGNNnrc7x6dy0HojJKvnCtybo23EBPllHMm5Dt0zEjDKilV_f6f8xE6TemRlMU5bWTzER3xmhHVyPoY_V2EcTLRpeBx6PEtDGAzdPhyHGcP2PgOL2E0OQxh7awZ8I2JZoRc_t0X7zbgYqEnYzMuGrdz3Lpt4ZwvaHbgc8J_XN7g5c1D9QsGs1Pfy5b7vY-Hl-sYpo2JT34NpXmxn-wT-tCbIcHpYT9B9z9_3C2W1dX1xeXi-1VluWpzxXhniBCmUz0hLW-pgpZIyrpaCto3K8slSAuCyp4S4H1PV0I1vFOkq4VsWn6Cvr3oTvNqhM4Wz9EMeopuLI50ME7_X_Fuo9dhq1sm22Yv8OUgEMPvGVLWo0sWhsF4CHPSTNRtXbzVoqCf36CPYY6-jLejFCv5SFao8xfKxpBShP7VDCV6l71-kz1_Bm9Do2s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2549276762</pqid></control><display><type>article</type><title>Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Brewczyński, Adam ; Jabłońska, Beata ; Mazurek, Agnieszka Maria ; Mrochem-Kwarciak, Jolanta ; Mrowiec, Sławomir ; Śnietura, Mirosław ; Kentnowski, Marek ; Kołosza, Zofia ; Składowski, Krzysztof ; Rutkowski, Tomasz</creator><creatorcontrib>Brewczyński, Adam ; Jabłońska, Beata ; Mazurek, Agnieszka Maria ; Mrochem-Kwarciak, Jolanta ; Mrowiec, Sławomir ; Śnietura, Mirosław ; Kentnowski, Marek ; Kołosza, Zofia ; Składowski, Krzysztof ; Rutkowski, Tomasz</creatorcontrib><description>Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV−) OPC, before and after radiotherapy/chemoradiotherapy (RT/CRT) and to assess the impact of these parameters on survival. One hundred twenty seven patients with HPV+ and HPV− OPC, treated with RT alone or concurrent chemoradiotherapy (CRT), were included. Patients were divided according to HPV status. Confirmation of HPV etiology was obtained from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue samples and/or extracellular circulating HPV DNA was determined. The pre-treatment and post-treatment laboratory blood parameters were compared in both groups. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and systemic immune inflammation (SII) index were calculated. The impact of these parameters on overall (OS) and disease-free (DFS) survival was analyzed. In HPV+ patients, a high pre-treatment white blood cells (WBC) count (>8.33 /mm3), NLR (>2.13), SII (>448.60) significantly correlated with reduced OS, whereas high NLR (>2.29), SII (>462.58) significantly correlated with reduced DFS. A higher pre-treatment NLR and SII were significant poor prognostic factors for both OS and DFS in the HPV+ group. These associations were not apparent in HPV− patients. There are different pre-treatment and post-treatment immune and hematological prognostic factors for OS and DFS in HPV+ and HPV− patients. The immune ratios could be considered valuable biomarkers for risk stratification and differentiation for HPV− and HPV+ OPC patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13133256</identifier><identifier>PMID: 34209764</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Age ; Blood ; Blood platelets ; Cancer ; Chemoradiotherapy ; Ethics ; Etiology ; Gender ; Genomes ; Hematology ; Hemoglobin ; Human papillomavirus ; Infections ; Inflammation ; Laboratories ; Leukocytes (neutrophilic) ; Lymphocytes ; Medical prognosis ; Monocytes ; Neutrophils ; Oncology ; Oropharyngeal cancer ; Paraffin ; Patients ; Platelets ; R&D ; Radiation therapy ; Research & development</subject><ispartof>Cancers, 2021-06, Vol.13 (13), p.3256</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-23da055ad9f0083819e80612d4651f7bc36e6ce516f10e3ff1b5973d90d456783</citedby><cites>FETCH-LOGICAL-c398t-23da055ad9f0083819e80612d4651f7bc36e6ce516f10e3ff1b5973d90d456783</cites><orcidid>0000-0003-2735-5664 ; 0000-0002-5495-2969 ; 0000-0002-3167-3326</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268778/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268778/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Brewczyński, Adam</creatorcontrib><creatorcontrib>Jabłońska, Beata</creatorcontrib><creatorcontrib>Mazurek, Agnieszka Maria</creatorcontrib><creatorcontrib>Mrochem-Kwarciak, Jolanta</creatorcontrib><creatorcontrib>Mrowiec, Sławomir</creatorcontrib><creatorcontrib>Śnietura, Mirosław</creatorcontrib><creatorcontrib>Kentnowski, Marek</creatorcontrib><creatorcontrib>Kołosza, Zofia</creatorcontrib><creatorcontrib>Składowski, Krzysztof</creatorcontrib><creatorcontrib>Rutkowski, Tomasz</creatorcontrib><title>Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer</title><title>Cancers</title><description>Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV−) OPC, before and after radiotherapy/chemoradiotherapy (RT/CRT) and to assess the impact of these parameters on survival. One hundred twenty seven patients with HPV+ and HPV− OPC, treated with RT alone or concurrent chemoradiotherapy (CRT), were included. Patients were divided according to HPV status. Confirmation of HPV etiology was obtained from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue samples and/or extracellular circulating HPV DNA was determined. The pre-treatment and post-treatment laboratory blood parameters were compared in both groups. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and systemic immune inflammation (SII) index were calculated. The impact of these parameters on overall (OS) and disease-free (DFS) survival was analyzed. In HPV+ patients, a high pre-treatment white blood cells (WBC) count (>8.33 /mm3), NLR (>2.13), SII (>448.60) significantly correlated with reduced OS, whereas high NLR (>2.29), SII (>462.58) significantly correlated with reduced DFS. A higher pre-treatment NLR and SII were significant poor prognostic factors for both OS and DFS in the HPV+ group. These associations were not apparent in HPV− patients. There are different pre-treatment and post-treatment immune and hematological prognostic factors for OS and DFS in HPV+ and HPV− patients. The immune ratios could be considered valuable biomarkers for risk stratification and differentiation for HPV− and HPV+ OPC patients.</description><subject>Age</subject><subject>Blood</subject><subject>Blood platelets</subject><subject>Cancer</subject><subject>Chemoradiotherapy</subject><subject>Ethics</subject><subject>Etiology</subject><subject>Gender</subject><subject>Genomes</subject><subject>Hematology</subject><subject>Hemoglobin</subject><subject>Human papillomavirus</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Monocytes</subject><subject>Neutrophils</subject><subject>Oncology</subject><subject>Oropharyngeal cancer</subject><subject>Paraffin</subject><subject>Patients</subject><subject>Platelets</subject><subject>R&D</subject><subject>Radiation therapy</subject><subject>Research & development</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtr3DAUhUVpaUKadbaCbrpxo4clW5tCGdpMIJDQPLZCI1_PKNiSK8lT8lv6Z6OZDKGNNnrc7x6dy0HojJKvnCtybo23EBPllHMm5Dt0zEjDKilV_f6f8xE6TemRlMU5bWTzER3xmhHVyPoY_V2EcTLRpeBx6PEtDGAzdPhyHGcP2PgOL2E0OQxh7awZ8I2JZoRc_t0X7zbgYqEnYzMuGrdz3Lpt4ZwvaHbgc8J_XN7g5c1D9QsGs1Pfy5b7vY-Hl-sYpo2JT34NpXmxn-wT-tCbIcHpYT9B9z9_3C2W1dX1xeXi-1VluWpzxXhniBCmUz0hLW-pgpZIyrpaCto3K8slSAuCyp4S4H1PV0I1vFOkq4VsWn6Cvr3oTvNqhM4Wz9EMeopuLI50ME7_X_Fuo9dhq1sm22Yv8OUgEMPvGVLWo0sWhsF4CHPSTNRtXbzVoqCf36CPYY6-jLejFCv5SFao8xfKxpBShP7VDCV6l71-kz1_Bm9Do2s</recordid><startdate>20210629</startdate><enddate>20210629</enddate><creator>Brewczyński, Adam</creator><creator>Jabłońska, Beata</creator><creator>Mazurek, Agnieszka Maria</creator><creator>Mrochem-Kwarciak, Jolanta</creator><creator>Mrowiec, Sławomir</creator><creator>Śnietura, Mirosław</creator><creator>Kentnowski, Marek</creator><creator>Kołosza, Zofia</creator><creator>Składowski, Krzysztof</creator><creator>Rutkowski, Tomasz</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2735-5664</orcidid><orcidid>https://orcid.org/0000-0002-5495-2969</orcidid><orcidid>https://orcid.org/0000-0002-3167-3326</orcidid></search><sort><creationdate>20210629</creationdate><title>Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer</title><author>Brewczyński, Adam ; Jabłońska, Beata ; Mazurek, Agnieszka Maria ; Mrochem-Kwarciak, Jolanta ; Mrowiec, Sławomir ; Śnietura, Mirosław ; Kentnowski, Marek ; Kołosza, Zofia ; Składowski, Krzysztof ; Rutkowski, Tomasz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-23da055ad9f0083819e80612d4651f7bc36e6ce516f10e3ff1b5973d90d456783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Blood</topic><topic>Blood platelets</topic><topic>Cancer</topic><topic>Chemoradiotherapy</topic><topic>Ethics</topic><topic>Etiology</topic><topic>Gender</topic><topic>Genomes</topic><topic>Hematology</topic><topic>Hemoglobin</topic><topic>Human papillomavirus</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Monocytes</topic><topic>Neutrophils</topic><topic>Oncology</topic><topic>Oropharyngeal cancer</topic><topic>Paraffin</topic><topic>Patients</topic><topic>Platelets</topic><topic>R&D</topic><topic>Radiation therapy</topic><topic>Research & development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brewczyński, Adam</creatorcontrib><creatorcontrib>Jabłońska, Beata</creatorcontrib><creatorcontrib>Mazurek, Agnieszka Maria</creatorcontrib><creatorcontrib>Mrochem-Kwarciak, Jolanta</creatorcontrib><creatorcontrib>Mrowiec, Sławomir</creatorcontrib><creatorcontrib>Śnietura, Mirosław</creatorcontrib><creatorcontrib>Kentnowski, Marek</creatorcontrib><creatorcontrib>Kołosza, Zofia</creatorcontrib><creatorcontrib>Składowski, Krzysztof</creatorcontrib><creatorcontrib>Rutkowski, Tomasz</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brewczyński, Adam</au><au>Jabłońska, Beata</au><au>Mazurek, Agnieszka Maria</au><au>Mrochem-Kwarciak, Jolanta</au><au>Mrowiec, Sławomir</au><au>Śnietura, Mirosław</au><au>Kentnowski, Marek</au><au>Kołosza, Zofia</au><au>Składowski, Krzysztof</au><au>Rutkowski, Tomasz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer</atitle><jtitle>Cancers</jtitle><date>2021-06-29</date><risdate>2021</risdate><volume>13</volume><issue>13</issue><spage>3256</spage><pages>3256-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV−) OPC, before and after radiotherapy/chemoradiotherapy (RT/CRT) and to assess the impact of these parameters on survival. One hundred twenty seven patients with HPV+ and HPV− OPC, treated with RT alone or concurrent chemoradiotherapy (CRT), were included. Patients were divided according to HPV status. Confirmation of HPV etiology was obtained from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue samples and/or extracellular circulating HPV DNA was determined. The pre-treatment and post-treatment laboratory blood parameters were compared in both groups. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and systemic immune inflammation (SII) index were calculated. The impact of these parameters on overall (OS) and disease-free (DFS) survival was analyzed. In HPV+ patients, a high pre-treatment white blood cells (WBC) count (>8.33 /mm3), NLR (>2.13), SII (>448.60) significantly correlated with reduced OS, whereas high NLR (>2.29), SII (>462.58) significantly correlated with reduced DFS. A higher pre-treatment NLR and SII were significant poor prognostic factors for both OS and DFS in the HPV+ group. These associations were not apparent in HPV− patients. There are different pre-treatment and post-treatment immune and hematological prognostic factors for OS and DFS in HPV+ and HPV− patients. The immune ratios could be considered valuable biomarkers for risk stratification and differentiation for HPV− and HPV+ OPC patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34209764</pmid><doi>10.3390/cancers13133256</doi><orcidid>https://orcid.org/0000-0003-2735-5664</orcidid><orcidid>https://orcid.org/0000-0002-5495-2969</orcidid><orcidid>https://orcid.org/0000-0002-3167-3326</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-06, Vol.13 (13), p.3256 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8268778 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Age Blood Blood platelets Cancer Chemoradiotherapy Ethics Etiology Gender Genomes Hematology Hemoglobin Human papillomavirus Infections Inflammation Laboratories Leukocytes (neutrophilic) Lymphocytes Medical prognosis Monocytes Neutrophils Oncology Oropharyngeal cancer Paraffin Patients Platelets R&D Radiation therapy Research & development |
| title | Comparison of Selected Immune and Hematological Parameters and Their Impact on Survival in Patients with HPV-Related and HPV-Unrelated Oropharyngeal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T09%3A16%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Selected%20Immune%20and%20Hematological%20Parameters%20and%20Their%20Impact%20on%20Survival%20in%20Patients%20with%20HPV-Related%20and%20HPV-Unrelated%20Oropharyngeal%20Cancer&rft.jtitle=Cancers&rft.au=Brewczy%C5%84ski,%20Adam&rft.date=2021-06-29&rft.volume=13&rft.issue=13&rft.spage=3256&rft.pages=3256-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13133256&rft_dat=%3Cproquest_pubme%3E2548400845%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2549276762&rft_id=info:pmid/34209764&rfr_iscdi=true |